The purpose of this study is to predict the costs of diagnosis, primary treatment of prostate cancer and the costs of overdetection when screening by PSA testing as done in the ERSPC trial is introduced population wide and to compare these with the costs of treatment when no screening is performed. Here, KLK3 is linked to prostate cancer.